Both NACT and adjuvant therapies are mainly based on the assessment of three biomarkers on tumor tissue from preoperative biopsies worldwide: estrogen receptors (ER), progesterone receptors (PR) and HER2 status [6,7]. Here, ERBB2 is linked to neoplasm.